Skip to content

Prospective Observational Study in Late-Stage Elderly Patients with Non-Valvular Atrial Fibrillation All Nippon AF In Elderly Registry -ANAFIE Registry-

Prospective Observational Study in Late-Stage Elderly Patients with Non-Valvular Atrial Fibrillation All Nippon AF In Elderly Registry -ANAFIE Registry- - ANAFIE Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000024006
Enrollment
30000
Registered
2016-09-12
Start date
2016-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Valvular Atrial Fibrillation

Interventions

None listed

Sponsors

Primary Medical Science Department Daiichi Sankyo Company, Limited.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Patients who have been given the definitive diagnosis of NVAF and who have the ability to attend the hospital at specified visits. If a new diagnosis of NVAF is to be given to a patient, ECG, Holter ECG, portable ECG, echocardiography, etc. should be performed to make a definitive diagnosis. (2)Patients aged 75 years or more at the time of informed consent (male or female patients) (3)Patients who have given informed consent in writing

Exclusion criteria

Exclusion criteria: (1)Patients who are currently participating/who are planning to participate in an interventional study (2)Patients who have been given the definitive diagnosis of mitral stenosis (3)Patients who have an artificial heart valve (mechanical valve or tissue valve prostheses) in their body (4)Patients who have experienced any cardiovascular event (stroke, myocardial infarction, cardiac intervention for cardiac events other than myocardial infarction, or heart failure requiring hospitalization) or any bleeding leading to hospitalization within one month before enrollment (5)Patients who have been diagnosed as having a life expectancy of less than one year for some kind of disease (6)Patients for whom participation in this study is inappropriate for other reason than those mentioned in the exclusion criteria above

Design outcomes

Primary

MeasureTime frame
Development of stroke/systemic embolism during the observation period

Secondary

MeasureTime frame
Occurrence of the following events during the observation period: (1)Hemorrhagic adverse events (major bleeding) (2)Stroke (3)Systemic embolism (4)Ischemic stroke (5)Hemorrhagic stroke (6)Intracranial hemorrhage (7)Cardiovascular events (stroke, myocardial infarction, cardiac intervention for cardiac events other than myocardial infarction, or heart failure requiring hospitalization) (8)Death from cardiovascular disease (death for which possibility of causal relationship with any cardiovascular factor cannot be excluded) (9)All-cause mortality

Countries

Japan

Contacts

Public ContactTakashi Takahashi

IQVIA Services Japan G.K. Real-World Evidence Services

anafie_office@iqvia.com06-7668-9053

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026